Vincenti F, et al. – Authors here discussed ten–year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4–weekly or 8–weekly. Although not statistically relevant, two–fold higher rates of biopsy–proven acute rejection (BPAR) were observed in patients administered belatacept every 8 weeks versus every 4 weeks.